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Objectives: Patients with asthma exacerbations requiring inpatient care com-
prise a sub-group at high risk of adverse asthma-related outcomes. The quality 
of care in these individuals can thus have substantial impact on the burden of 
asthma. The purpose of this study was to provide a broad picture on the out-
comes associated with different treatment strategies after discharge from 
an asthma-related admission. MethOds: Using administrative health data 
of British Columbia, Canada (1997-2012), we created a cohort of individuals 
discharged from an episode of asthma-related hospitalization. Exposure was 
assessed in the 60 days after discharge, and was categorized as no controller 
treatment, monotherapy with inhaled corticosteroids (ICS), or combination ther-
apy with ICS plus long-acting beta agonists (LABA). Safety (re-admission), adher-
ence (proportion of days covered [PDC] with controller medications, and health 
resource use (asthma-related costs) outcomes were ascertained in the next 365 
days. Generalized propensity scores were calculated to achieve balance in the 
distribution of potential confounders across exposure groups. Results: The final 
cohort included 1,864; 848; and 954 post-discharge periods, respectively, for no 
treatment, ICS-only, and ICS+LABA groups. Asthma-related admissions were 
significantly lower in the ICS-only groups compared with no treatment group 
(RR= 0.69 [95%CI 0.55 - 0.87], P= 0.001), but were similar between the ICS+LABA and 
ICS-only groups (RR= 0.96 [95% CI 0.73 - 1.27], P= 0.787). The PDC by a controller 
medication was significantly higher in the ICS group compared with no treatment 
(difference of 8.7% [95% CI 6.8% - 10.5%], P< 0.001), as well as PDC by ICS+LABA 
compared with PDC by ICS (difference of 7.2% [95%CI 4.7% - 9.6%], P< 0.001). There 
were no differences in costs across the three groups. cOnclusiOns: Initiation 
of controller medications in the post-discharge period was associated with sig-
nificant benefits. The higher adherence to controller medication between the 
ICS+LABA compared with ICS-only group can translate to better outcomes in 
the long term.
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Objectives: To investigate smoking cessation behaviors in Japanese current smok-
ers (CS) and former smokers (FS). MethOds: An online survey of Japanese men 
and women ≥ 20 years of age who were CS or FS was conducted. CS were those who 
smoked any number of cigarettes at the time of the survey (24–27 June 2013); FS 
were those who had smoked any number of cigarettes in the past but did not con-
sider themselves smokers at the time of the survey. Clinical and socio-demographic 
characteristics (age, gender, level of education, and level of nicotine dependence 
[Fagerström Test for Nicotine Dependence]) as well as smoking and smoking ces-
sation history, were assessed through a web-based questionnaire. We set primary 
outcome measures as the number of past quit attempts and the time to relapse 
(duration of smoking abstinence). Secondary outcome measures included methods 
used to achieve smoking cessation, and reasons for wanting to quit. Results: A 
total of 1261 eligible Japanese subjects were included in the survey (CS, n = 631; FS, 
n = 630). Mean age and gender distribution were broadly similar between the groups. 
Nearly half (45.6%) of CS had never attempted to quit smoking. Of those who had 
attempted to quit smoking, one single quit attempt was the most common for both 
CS and FS (19.0 vs. 39.0%). The estimated median time to relapse was 105 days (FS 
and CS combined). Unaided smoking cessation was the most common method both 
for CS and FS (78.2 vs. 63.4%). cOnclusiOns: Our observations reveal the actual 
smoking cessation behaviors in a Japanese population, and could be combined 
with other data in economic evaluation models of smoking cessation interventions 
in Japan to identify appropriate measures to reduce the prevalence of smoking.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is associated with 
elevated levels of pulmonary and systemic inflammatory markers which may lead 
to high prevalence of inflammation-related conditions. This study examines the 
prevalence and demographic predictors of inflammation-related multimorbidity 
among Medicaid beneficiaries with COPD. MethOds: Observational retrospec-
tive cohort study using multiple years (2005-2006) of data from Medicaid Analytic 
eXtract (MAX) files of California (CA), Illinois (IL), New York (NY) and Texas (TX). 
Individuals with COPD (n = 37,151) were identified using ICD-9-CM codes for 
chronic bronchitis (491.xx), emphysema (492.xx), or unspecified chronic airway 
obstruction (496.xx). Inflammation-related multimorbidity included: cardio-vascu-
lar disease, depression, diabetes mellitus, hypertension, hyperlipidemia and mus-
culoskeletal disorders. This variable was categorized into: (i) both physical/mental 
illness (IF_PHY/MI); (ii) physical illness only (IF_PHY/no MI); (iii) mental illness 
only (IF_no PHY/ MI); (iv) NONE. Unadjusted group differences were tested using 
the chi-square statistics. Multinomial logistic regression was used to analyze the 
association between demographic predictors and inflammation-related multimor-
bidity. All analyses were conducted using SAS. Results: Overall, 78.9% of study 
population had an inflammation-related multimorbidity, of which 22.9% had IF_
we sought to determine the prevalence of PIMs for older adults in Emilia-Romagna, 
Italy, using the updated Maio criteria. We also evaluated patient and general prac-
titioner (GP) characteristics related to inappropriate prescribing. MethOds: Older 
adults (≥ 65) in 2012 were evaluated in a one-year retrospective study using adminis-
trative health care data. The 2011 Maio criteria includes 25 medications reimbursed 
by the Italian National Formulary, in the following categories in terms of severity: 
16 medications that ‘should always be avoided,’ 3 that are ‘rarely appropriate,’ and 6 
that have ‘some indications although they are often misused.’ To evaluate the extent 
of associations between patient and GP related characteristics, we used generalized 
estimating equations with an exchangeable covariance design to fit a robust logistic 
regression model. Results: A total of 865,354 older adults were in the cohort and 
28% had at least one PIM. Of the entire cohort, 8%, 10%, and 14% of individuals 
were prescribed at least one medication that ‘should always be avoided,’ ‘rarely 
appropriate,’ and has ‘some indications but are often misused,’ respectively. Older 
patients (≥ 75) and females were more likely to be exposed to PIMs. 2,923 GPs were 
identified in the region that prescribed at least one PIM, of which older (≥ 56) GPs, 
male GPs, and solo practice GPs were more likely to prescribe PIMs to their older 
patients. cOnclusiOns: The high prevalence of PIM exposure among older adults 
is a substantial issue in the region. Knowing how patient and GP characteristics 
relate to PIMs exposure may improve the design and targeting of initiatives for 
improving prescribing safety in this population.
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Objectives: Overuse of antibiotics in children is a growing concern in the US. 
One of the important HEDIS quality measures used to compare performance of 
health plans incorporates appropriate prescribing of antibiotics for children with 
pharyngitis. The current study examined this measure over four years to deter-
mine if physician behavior had changed over time. MethOds: Patients aged 2-18 
diagnosed with pharyngitis (ICD-9-CM 462, 463 and 034.0) on a medical claim 
(‘index’) and dispensed an antibiotic were identified in administrative claims data 
from the Truven Health MarketScan® Research databases (2008-2012). From this 
eligible population, the proportion of patients having evidence of a streptococ-
cus test in the seven-day period from three days prior to index through three 
days post-index was calculated. A higher rate represents better performance (i.e., 
appropriate testing). Rates were examined overall and by age group. Results: In 
fiscal year (FY) 2009, 68.9% of eligible patients had evidence of a streptococcus test. 
Appropriate testing rates were highest for patients aged 5-7 and 8-10 (76.1% and 
75.1%, respectively) and lowest for those aged 14-16 and 17-18 (62.0% and 59.9%, 
respectively). The rate of appropriate testing grew slightly in FY2010 to 70.2% with 
very similar age-group specific rates. In FY2011, the overall rate grew by nearly 
6% to 74.3%. Age group trends continued, with 80.3% of patients aged 5-7 and 
78.3% of patients aged 8-10 appropriately tested. In FY2012 the overall rate grew 
to 76.0%, with patients aged 5-7 and 8-10 continuing to have the highest rate of 
testing (81.1% and 80.8%, respectively) and those aged 14-16 and 17-18 the low-
est rate (71.6% and 67.0%, respectively). cOnclusiOns: The rate of appropriate 
testing for antibiotic use in children with pharyngitis increased by 10% between 
FY2009 and FY2012. While the trend is moving in the right direction, significant 
room for improvement remains.
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Objectives: Tiotropium is widely used in patients with chronic obstructive pul-
monary disease (COPD), and is effective in reducing the risk of COPD exacerba-
tions. However, controversies exist around its safety, especially with regard to 
cardiac arrhythmia. This study aimed to evaluate the risk of tiotropium for cardiac 
arrhythmia hospitalization. MethOds: A self-controlled case series was under-
taken using the IMS LifeLink Health Plan Claims Databases. COPD patients aged 
45 years or older and hospitalized with cardiac arrhythmia during the observation 
period, from 2008 to 2011, were included. The exposure periods were defined for 
each patient as the dispensing periods of tiotropium plus an additional following 
30 days as the wash-out period. The remaining time within the observation period 
in which patients were not using tiotropium were the unexposed periods. The inci-
dence rate ratio (IRR) of cardiac arrhythmia hospitalization was calculated by com-
paring exposed and unexposed periods using multivariable conditional Poisson 
regression. Results: A total of 86,108 COPD patients with cardiac arrhythmia hos-
pitalizations were included. Among those, 14,398 patients (16.7%) received tiotro-
pium. The average age of the cohort at the beginning of the observation period was 
72.3 ± 12.4 years. The median follow-up time was 1,216 days (inter-quartile range; 
731 – 1,461 days). The IRR of tiotropium on cardiac arrhythmia hospitalization 
was 1.18 [95% confidence interval (CI) 1.12 – 1.24]. The IRR was highest in the first 
14 days of initiation of tiotropium [IRR 1.94; 95% CI 1.71 – 2.21] and slightly 
decreased over time but remained statistically significant. cOnclusiOns: 
Tiotropium was associated with an increased risk of cardiac arrhythmia hospi-
talization. The risk is highest in the first 14 days of initiation of tiotropium and 
decreased overtime. Patients initiating tiotropium should be closely monitored 
for cardiac arrhythmia.
